NCT01785836

An Extension Study to Assess the Safety, Tolerability, Efficacy, and Treatment Adherence of Dapsone in Acne Vulgaris

• Status: Withdrawn
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Allergan · Industry
• Sex: All
• Age: 12 Years – 35 Years
• Healthy volunteers: Not accepted

Summary

This study will assess the safety, tolerability, and efficacy of dapsone in subjects with acne vulgaris following 12 weeks of treatment.

Conditions

• Acne Vulgaris

Interventions

Type	Name	Description
DRUG	Dapsone Formulation A	Dapsone Formulation A applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
DRUG	Dapsone Formulation B	Dapsone Formulation B applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
DRUG	Dapsone Formulation C	Dapsone Formulation C applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
DRUG	Dapsone 5% Gel	Dapsone 5% gel (ACZONE®) applied twice daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.

Timeline

• Start date: 2013-03-01
• Primary completion: 2013-10-01
• Completion: 2013-10-01
• First posted: 2013-02-07
• Last updated: 2013-02-25